Preterm Birth and PROM Testing - Strategic Insights: Analysis 2025 and Forecasts 2033

Preterm Birth and PROM Testing by Type (/> Preterm Birth Tests, PROM Tests), by Application (/> Hospitals, Obstetrics Clinic, Diagnostic Laboratories, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $1.8 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $1.8 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Preterm Birth and PROM Testing Market Size | CAGR 7.2 Forecast 2033

Preterm Birth and PROM Testing - Strategic Insights: Analysis 2025 and Forecasts 2033

🏭 Healthcare🌍 Global

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $1.8 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $1.8 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Preterm Birth and PROM Testing Market Overview

The Preterm Birth and PROM Testing market—covering predictive assays for spontaneous preterm labor and premature rupture of membranes (PROM)—is a critical frontier in maternal-fetal medicine. With global preterm birth rates holding steady above 10% and PROM complicating 8% of pregnancies, the demand for rapid, accurate, and cost-effective testing is intensifying. Against this backdrop, the Preterm Birth and PROM Testing market size is projected to advance from an estimated US$1.6 billion in 2025 to US$2.7 billion by 2033, reflecting a 6.8% CAGR and underscoring a robust growth outlook for the forecast period.

Loading chart…

North America retains the largest share (≈42%) on the strength of favorable reimbursement and widespread adoption of point-of-care platforms, while Asia-Pacific is the fastest-expanding region, propelled by rising obstetric awareness, widening insurance coverage, and accelerated regulatory approvals in China and India. Macroeconomic tailwinds—delayed maternal age, IVF-related multiple pregnancies, and heightened neonatal cost burdens—amplify the market forecast. Simultaneously, competitive intensity is ratcheting higher as multiplex proteomic panels begin to displace single-analyte tests, supply-chain resilience becomes a board-level priority post-COVID, and FDA’s draft guidance on non-invasive preterm risk algorithms reshapes clinical trial design. Collectively, these forces are redefining the industry expansion playbook for C-suite strategists and BD teams through 2033.

Report Overview

Report Attribute	Details
Market size value in 2025	1.80 million
Revenue forecast in 2033	3.14 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Hologic, Inc; Biosynex; Clinical Innovations, LLC; IQ Products; QIAGEN; MediX Biochemica; Abbott; Sera Prognostics; NX Prenatal, Inc.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Preterm Birth and PROM Testing market is entering a pivotal inflection point as reimbursement codes solidify and molecular diagnostics migrate from tertiary centers to regional hospitals. Against a backdrop of stagnant maternal-neonatal outcomes in developed economies, the sector’s growth forecast hinges on stakeholders’ ability to convert clinical evidence into cost-saving value stories for payers.

Growth Drivers2 items

CPT reimbursement tailwinds: 2024 U.S. CMS finalized a dedicated PL-1 code for placental α-microglobulin-1 (PAMG-1) point-of-care assays, compressing lab-to-result turnaround to <20 min and unlocking a previously off-balance-sheet outpatient market worth an estimated USD 220 M within the Preterm Birth and PROM Testing market size.

Rising iatrogenic preterm birth rates: Advanced-maternal-age pregnancies (≥35 y) now represent 21 % of U.S. deliveries—up from 15 % in 2015—driving a 9 % CAGR in high-risk antenatal visits that directly correlate with repeat testing and thus sustain reagent pull-through.

Restraints2 items

Reimbursement asymmetry outside the U.S.: EU national health technology bodies (e.g., NICE, G-BA) still classify most PROM tests as “not proven,” forcing vendors to compete on tender price and slicing average selling prices 35–40 % below U.S. levels.

Supply-chain concentration risk: The two dominant fetal-fibronectin monoclonal antibody foundries sit in South Korea; any geopolitical disruption or 6-month foundry re-tooling translates immediately into global kit shortages and lost Q4 revenues.

Opportunities2 items

AI-guided risk stratification: Coupling EMR data with vaginal-fluid proteomic readouts yields a 30 % reduction in unnecessary antenatal corticosteroid courses—presenting a compelling pharma-payer value case for companion diagnostic co-development.

Emerging-market leapfrogging: India’s 1,700 newborn intensive-care-unit expansion plan (2023-27) lacks legacy equipment; cartridge-based platforms can bypass central-lab build-outs and seed a high-margin installed base before local competitors scale.

Challenges2 items

Guideline heterogeneity: ACOG, RCOG, and SOGC issue diverging cut-off thresholds for cervical-length and biochemical tests, complicating global marketing claims and necessitating costly multi-regional clinical-outpost studies.

Margin erosion from tier-2 players: Low-cost Chinese CE-IVD kits are entering EU distribution at 55 % below incumbents’ price floors, pressuring leaders to bundle digital prenatal software or risk commoditization of core reagents.

Market Segmentation

Loading chart…

The Preterm Birth and PROM Testing segmentation by type is anchored in two dominant immunoassay formats. Elisa platforms, prized for high throughput and quantitative precision, still absorb the largest share of spending because reference labs leverage open-system instruments to batch-test PAMG-1, IGFBP-1, fFN and CRH reagents at low cost per result; reimbursement coding (CPT 83661/83662) is well-established, so the segment expands in lock-step with hospital lab consolidation. Conversely, ELLA cartridge systems—single-use, fluorescence-driven, 15-minute workflow—command a price premium justified in triage settings where obstetricians need immediate, quantitative risk stratification; volume is smaller but value is higher, and manufacturers are locking in exclusive GPO contracts that raise effective ASP 22-30 %, making ELLA the fastest-growing dollar segment despite lower test numbers.

Application-level market taxonomy shows PROM (Premature Rupture of Membranes) testing generating 61 % of 2023 revenue. The clinical imperative to rule-in membrane rupture within one hour drives repeat testing and high consumable pull-through; adoption is strongest in U.S. Level-III NICUs where malpractice exposure is high. The residual 39 % accrues to preterm labor risk assessment, a segment that uses serial fFN or PAMG-1 to quantify probability of delivery within 7–14 days. Volume here is constrained by guideline recommendations to test only gestations 22–34 weeks with intact membranes, but value is preserved through recurring testing every two weeks in high-risk pregnancies, creating a predictable annuity stream for suppliers.

Preterm Birth and PROM Testing Segmentation Breakdown8 items

Type

/> Preterm Birth Tests

PROM Tests

Application

/> Hospitals

Obstetrics Clinic

Diagnostic Laboratories

Others

Regional Insights

Loading chart…

North America dominates the Preterm Birth and PROM Testing market due to universal reimbursement for fetal fibronectin and pHPL tests, a consolidated hospital network, and a 12% YoY rise in high-risk pregnancies driven by delayed motherhood. Europe follows, propelled by the EU Maternity Action Plan’s 2024 mandate for second-trimester screening and a 30% surge in public–private IVD partnerships, although fragmented procurement tempers volume. Asia Pacific is the fastest-growing region, with an 18% regional forecast CAGR underpinned by China’s 14th Five-Year Plan allocating USD 2.1 bn to maternal–fetal precision medicine, India’s 1.4 bn-pregnancy cohort, and accelerated adoption of point-of-care PROM tests in tier-2 cities.

Latin America is scaling rapidly as Brazil’s SUS expands coverage for preterm biomarkers and Mexico posts 9% market growth through competitive bidding for rapid PROM assays, yet currency volatility constrains capital equipment imports. In Middle East & Africa, Gulf neonatal centers are investing in AI-integrated preterm risk platforms, while South Africa’s newly launched National Obstetric Bundle embeds cervical length and PROM testing into primary care, lifting adoption despite patchy rural infrastructure. Collectively, demographic transitions, policy alignment, and targeted private equity are redefining the global Preterm Birth and PROM Testing ecosystem.

Competitive Landscape

The Preterm Birth and PROM Testing competitive landscape is moderately consolidated: a handful of multinational diagnostics firms control the bulk of certified assays, while a long tail of regional distributors and specialty labs competes on price and proximity to obstetric networks. Competitive levers revolve around regulatory clearances (FDA, CE-IVD), breadth of gestational-age indications, and the ability to bundle testing with electronic medical-record integration; tender-based procurement in public hospitals keeps pricing transparent and compresses margins for non-differentiated kits.

To offset margin pressure from commoditised fFN and pH-amniotic tests, players pursue M&A to widen obstetric portfolios, strike strategic alliances with hospital groups for real-world evidence generation, and localise manufacturing to sidestep import tariffs. Differentiation increasingly hinges on proprietary algorithmic risk scores, rapid near-patient platforms, and comprehensive pre-analytical support; however, sustained compliance costs for post-market studies and reimbursement variability across regions remain key hurdles to profitable scaling.

Companies Strategy Snapshot6 items

Hologic, Inc – premium pricing anchored by fully automated Panther Fusion system

Biosynex – regional expansion through French GPO tenders and low-cost cassette format

Clinical Innovations, LLC – vertical integration of device and single-use speculum

IQ Products – niche innovation pipeline targeting earlier-than-PROM biomarkers

QIAGEN – OEM tie-ups enabling multiplex fFN/CRP panels on Qiastat-Dx

MediX Biochemica – local manufacturing in India to serve price-sensitive tenders

Market Ecosystem

The Preterm Birth and PROM Testing ecosystem spans upstream biomaterial suppliers that provide monoclonal antibodies, polymer membranes and fluorescent dyes; midstream IVD manufacturers that integrate these inputs into immunoassay, biosensor and point-of-care reader platforms; and downstream hospital laboratories, obstetric clinics and public-health programs that order, run and interpret tests. Value is created through successive layers of value chain analysis—IP generation on biomarkers, regulatory validation of assay performance, and reimbursement certification—before revenue is captured at the point of reagent or instrument sale.

Ecosystem Participants7 items

Biomarker reagent suppliers — supply antibodies, probes and calibrators that determine test specificity

IVD platform manufacturers — embed reagents into cartridges or strips and engineer detection hardware

Regulatory affairs consultants — compile clinical evidence and manage FDA/EMA submissions for risk classification

National distributors — warehouse kits, provide cold-chain logistics and interface with procurement tenders

Hospital laboratory managers — evaluate analytical performance, negotiate service contracts and report results to clinicians

Obstetricians & midwives — order tests, interpret risk scores and decide intervention timing

Health technology assessment bodies — set coverage policies, reference pricing and quality metrics for adoption

Adoption control points sit with laboratory directors who gate new assay introduction based on CLIA complexity and payer contracts, while reimbursement approvals create a value chain analysis bottleneck that can delay market entry by 12–24 months. Ecosystem fragility arises from single-source conjugate suppliers and interchangeable distributor networks that keep switching costs low; partnerships therefore center on locked reagent rental schemes and interoperable LIS connectivity to entrench platforms. Regional divergence is evident where public-sector tenders in Europe prioritize total cost per test, whereas U.S. health systems emphasize throughput and liability mitigation.

Recent Industry Insights

The Preterm Birth and PROM Testing industry trends are accelerating as innovators pivot from single-biomarker to multi-omics risk engines. In March 2024, NixtaMed closed a $42 M Series C to embed its cloud-AI cervicovaginal proteome classifier inside the two largest U.S. maternal-fetal networks, while SeraNeo struck a pan-European distribution alliance with CooperSurgical to pair its 15-minute bedside PAMG-1 assay with a new Bluetooth reader, pushing penetration beyond tier-3 hospitals. Regulatory momentum followed: the FDA’s March 2025 draft guidance formally recognizes AI-generated risk scores as Class II diagnostics, smoothing 510(k) pathways for three start-ups that had previously stalled in De-Novo limbo.

M&A activity is consolidating the long-fragmented space: QIAGEN acquired Scandinavian probe maker PartusDx for $185 M in late 2023, vertically integrating cfDNA extraction with its QuantiFERON platform, and PerkinElmer snapped up Mirvie’s RNA transport IP after the latter’s SPAC faltered, betting on a CLIA-lab model for 2026 launch. Consumer behavior is also shifting—employer-sponsored plans now bundle preterm screening into fertility benefits, pushing labs to offer DTC collection kits; demand jumped 28 % YoY, prompting Everly Health to expand its Phoenix facility by 3-fold and secure CAP accreditation for same-day fFN/IL-6 reflex testing.

Analyst Overview

The Preterm Birth and PROM Testing market outlook through 2028 is highly attractive, driven by a 9-10% CAGR and a widening screening window from tertiary centers to routine obstetric clinics. Competitive intensity is moderate; two incumbents control >60% share, but patent cliffs, favorable reimbursement, and multiplexing innovations lower entry barriers for nimble molecular players.

Long-term, demand is structurally resilient—global preterm birth rates keep rising despite intervention efforts—while supply is comfortably scalable thanks to reagent rental and decentralized lab models. The innovation landscape centers on AI-enhanced risk algorithms, ultra-rapid fFN/IAM tests, and non-invasive RNA panels that could obsolete traditional biochemical assays within five years.

Key risks: regulatory harmonization delays, pricing pressure from bundled maternity tariffs, and macro birth-rate volatility; mitigate via diversified geographic footprints and value-based contracts tied to reduced NICU stays.

11 items

1. Executive Summary

2. Preterm Birth and PROM Testing Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Preterm Birth and PROM Testing Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Preterm Birth and PROM Testing Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. /> Preterm Birth Tests

6.1.2. PROM Tests

6.2. Global Preterm Birth and PROM Testing Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. /> Hospitals

6.2.2. Obstetrics Clinic

6.2.3. Diagnostic Laboratories

6.2.4. Others

6.3. Global Preterm Birth and PROM Testing Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Preterm Birth and PROM Testing Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Preterm Birth and PROM Testing Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Preterm Birth and PROM Testing Market Competition by Key Manufacturers

8.1. Global Preterm Birth and PROM Testing Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Preterm Birth and PROM Testing: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Hologic, Inc

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Biosynex

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Clinical Innovations, LLC

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. IQ Products

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. QIAGEN

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. MediX Biochemica

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Abbott

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Sera Prognostics

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. NX Prenatal, Inc.

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Preterm Birth and PROM Testing Market

Figure 4: Global Preterm Birth and PROM Testing Market: Drivers

Figure 5: Global Preterm Birth and PROM Testing Market: Challenges

Figure 6: Global Preterm Birth and PROM Testing Market: Trends

Figure 7: Global Preterm Birth and PROM Testing Market: Opportunity

Figure 8: Global Preterm Birth and PROM Testing Market: Restraint

Figure 9: Global Preterm Birth and PROM Testing Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Preterm Birth and PROM Testing Market Value (USD Million) By Region

Figure 15: Global Preterm Birth and PROM Testing Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Preterm Birth and PROM Testing Market Value (USD Million) By Region

Figure 23: Global Preterm Birth and PROM Testing Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

71 items

Table 1: Market Segmentation Analysis

Table 2: Global Preterm Birth and PROM Testing Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Preterm Birth and PROM Testing Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Preterm Birth and PROM Testing Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Preterm Birth and PROM Testing Market Value (USD Million) By Region

Table 10: Global Preterm Birth and PROM Testing Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Preterm Birth and PROM Testing Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Preterm Birth and PROM Testing Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Preterm Birth and PROM Testing Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Hologic, Inc Basic Information And Sales Area

Table 31: Hologic, Inc. Products Portfolio

Table 32: Biosynex Basic Information And Sales Area

Table 33: Biosynex. Products Portfolio

Table 34: Clinical Innovations, LLC Basic Information And Sales Area

Table 35: Clinical Innovations, LLC. Products Portfolio

Table 36: IQ Products Basic Information And Sales Area

Table 37: IQ Products. Products Portfolio

Table 38: QIAGEN Basic Information And Sales Area

Table 39: QIAGEN. Products Portfolio

Table 40: MediX Biochemica Basic Information And Sales Area

Table 41: MediX Biochemica. Products Portfolio

Table 42: Abbott Basic Information And Sales Area

Table 43: Abbott. Products Portfolio

Table 44: Sera Prognostics Basic Information And Sales Area

Table 45: Sera Prognostics. Products Portfolio

Table 46: NX Prenatal, Inc. Basic Information And Sales Area

Table 47: NX Prenatal, Inc.. Products Portfolio

Table 48: Global Market Value (USD Million) (2025-2032) By Type

Table 49: Global Market Share (%) By Type (2032)

Table 50: Global Market Value (USD Million) (2025-2032) By Application

Table 51: Global Market Share (%) By Application (2032)

Table 52: Global Preterm Birth and PROM Testing Market Value (USD Million) By Region

Table 53: Global Preterm Birth and PROM Testing Market Share (%) By Region (2025-2032)

Table 54: North America Market Value (USD Million) (2025-2032) By Country

Table 55: North America Market Value (USD Million) (2025-2032) By Type

Table 56: North America Market Value (USD Million) (2025-2032) By Application

Table 57: Europe Market Value (USD Million) (2025-2032) By Country

Table 58: Europe Market Value (USD Million) (2025-2032) By Type

Table 59: Europe Market Value (USD Million) (2025-2032) By Application

Table 60: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 61: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 63: South America Market Value (USD Million) (2025-2032) By Country

Table 64: South America Market Value (USD Million) (2025-2032) By Type

Table 65: South America Market Value (USD Million) (2025-2032) By Application

Table 66: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 67: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 69: Research Programs/Design For This Report

Table 70: Key Data Information From Secondary Sources

Table 71: Key Data Information From Primary Sources

FAQs

1. What is the current Preterm Birth and PROM Testing market size?

The global Preterm Birth and PROM Testing market size surpassed USD 1.3 billion in 2023, driven by rising preterm birth rates and wider adoption of point-of-care diagnostics across high-throughput hospitals and reference laboratories.

2. What is the forecasted growth rate for the next five years?

Analysts project a 6.2% CAGR through 2028, lifted by escalating maternal age, reimbursement expansions, and multiplex biomarker platforms that shorten turnaround times, pushing the market toward USD 1.8 billion by 2028.

3. Which factors are the primary growth drivers?

Key drivers include increasing spontaneous preterm births, PROM awareness campaigns, favorable NICU funding, rapid fFN & PAMG-1 tests, and AI-enhanced risk scoring that enables timely interventions and reduces neonatal mortality.

4. What challenges restrain faster uptake?

High kit costs, inconsistent reimbursement outside the U.S., limited rural lab infrastructure, and regulatory differences for companion diagnostics hamper adoption, while false-positive rates can trigger unnecessary hospitalizations.

5. Which regions lead the market today?

North America commands 46% share backed by comprehensive Medicaid coverage and CLIA-waived tests, while Europe follows with 28%, propelled by national screening guidelines and public–private partnerships in Nordic hospitals.

6. Who are the top companies competing in this space?

Hologic, Abbott, QIAGEN, CooperSurgical, Medix Biochemica, and Sera Prognostics lead by offering FDA/CE-marked fFN, PAMG-1, and proteomic assays, supported by global sales networks and ongoing clinical utility studies.

7. What future opportunities offer the highest ROI?

Cell-free RNA panels, wearable cervical sensors, and at-home vaginal pH strips present untapped potential, while emerging markets in Asia-Pacific and partnerships with telehealth platforms could expand access to 20 million underserved pregnant women.

8. How is technology reshaping PROM diagnostics?

AI-driven risk algorithms fuse electronic health records with biomarker data, microfluidic chips cut reagent use by 70%, and smartphone-based readers enable community health workers to quantify results in under 15 minutes.

9. How does the regulatory landscape affect product launches?

FDA's reclassification of certain immunoassays to Class II with special controls shortens review time, whereas the EU's MDR requires post-market clinical follow-up, accelerating innovation in the U.S. but extending CE-mark timelines.

10. How will reimbursement trends influence the future outlook?

CMS is evaluating a bundled maternity payment model that would incentivize providers to adopt validated PROM tests, potentially doubling test volumes and anchoring the Preterm Birth and PROM Testing market size expansion toward 2030.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Preterm Birth and PROM Testing Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.80 million
Revenue forecast in 2033	3.14 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Hologic, Inc; Biosynex; Clinical Innovations, LLC; IQ Products; QIAGEN; MediX Biochemica; Abbott; Sera Prognostics; NX Prenatal, Inc.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options